1. Market Research
  2. > Celon Pharma Sp. z o.o. - Product Pipeline Review - 2013

Celon Pharma Sp. z o.o. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 29 pages

Celon Pharma Sp. z o.o. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Celon Pharma Sp. z o.o. - Product Pipeline Review - 2013” provides data on the Celon Pharma Sp. z o.o.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celon Pharma Sp. z o.o.’s corporate website, SEC filings, investor presentations and featured press releases, both from Celon Pharma Sp. z o.o. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Celon Pharma Sp. z o.o. - Brief Celon Pharma Sp. z o.o. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Celon Pharma Sp. z o.o. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Celon Pharma Sp. z o.o. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Celon Pharma Sp. z o.o.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Celon Pharma Sp. z o.o.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Celon Pharma Sp. z o.o. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Celon Pharma Sp. z o.o.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Celon Pharma Sp. z o.o..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Celon Pharma Sp. z o.o. and identify potential opportunities in those areas.

Table Of Contents

Celon Pharma Sp. z o.o. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Celon Pharma Sp. z o.o. Snapshot 5
Celon Pharma Sp. z o.o. Overview 5
Key Information 5
Key Facts 5
Celon Pharma Sp. z o.o. - Research and Development Overview 6
Key Therapeutic Areas 6
Celon Pharma Sp. z o.o. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Celon Pharma Sp. z o.o. - Pipeline Products Glance 10
Celon Pharma Sp. z o.o. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Celon Pharma Sp. z o.o. - Drug Profiles 12
CPL-200-075 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
CPL-202-100 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
CPL-204-015 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
CPL-407-22 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Drug Targeting Anaplastic Lymphoma Kinase 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Drug Targeting Fibroblast Growth Factor Receptor 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Drug Targeting G-Protein Coupled Receptor 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Drug Targeting Phosphoinositide 3-Kinase 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Drug Targeting Wnt/Beta-catenin Pathway 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Celon Pharma Sp. z o.o. - Pipeline Analysis 21
Celon Pharma Sp. z o.o. - Pipeline Products by Therapeutic Class 21
Celon Pharma Sp. z o.o. - Pipeline Products By Target 23
Celon Pharma Sp. z o.o. - Pipeline Products by Route of Administration 24
Celon Pharma Sp. z o.o. - Pipeline Products By Mechanism of Action 25
Celon Pharma Sp. z o.o. - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables

Celon Pharma Sp. z o.o., Key Information 5
Celon Pharma Sp. z o.o., Key Facts 5
Celon Pharma Sp. z o.o. - Pipeline by Indication, 2013 7
Celon Pharma Sp. z o.o. - Pipeline by Stage of Development, 2013 8
Celon Pharma Sp. z o.o. - Monotherapy Products in Pipeline, 2013 9
Celon Pharma Sp. z o.o. - Preclinical, 2013 10
Celon Pharma Sp. z o.o. - Discovery, 2013 11
Celon Pharma Sp. z o.o. - Pipeline By Therapeutic Class, 2013 22
Celon Pharma Sp. z o.o. - Pipeline By Target, 2013 23
Celon Pharma Sp. z o.o. - Pipeline By Route of Administration, 2013 24
Celon Pharma Sp. z o.o. - Pipeline Products By Mechanism of Action, 2013 26
Celon Pharma Sp. z o.o., Other Locations 27

List of Figures

Celon Pharma Sp. z o.o. - Pipeline by Indication, 2013 7
Celon Pharma Sp. z o.o. - Pipeline by Stage of Development, 2013 8
Celon Pharma Sp. z o.o. - Monotherapy Products in Pipeline, 2013 9
Celon Pharma Sp. z o.o. - Pipeline By Therapeutic Class, 2013 21
Celon Pharma Sp. z o.o. - Pipeline Products By Mechanism of Action, 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.